GSK2033
GSK2033 is a LXR antagonist with pIC50s of 7 and 7.4 for LXRα or LXRβ, respectively.
Product Specifications
CAS Number
1221277-90-2
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
LXR
Type
Reference compound
Related Pathways
Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor
Applications
Metabolism-sugar/lipid metabolism
Field of Research
Metabolic Disease
Assay Protocol
https://www.medchemexpress.com/GSK2033.html
Concentration
10mM
Purity
99.37
Solubility
DMSO : 11.11 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
O=S(C1=C(C)C=C(C)C=C1C)(N(CC2=CC=C(C3=CC=CC(S(=O)(C)=O)=C3)C=C2)CC4=CC=C(C(F)(F)F)O4)=O
Molecular Formula
C29H28F3NO5S2
Molecular Weight
591.66
Precautions
H302, H315, H319, H335
References & Citations
[1]Zuercher WJ, et al. Discovery of tertiary sulfonamides as potent liver X receptor antagonists. J Med Chem. 2010 Apr 22;53 (8) :3412-6.|[2]Griffett K, et al. Promiscuous activity of the LXR antagonist GSK2033 in a mouse model of fatty liver disease. Biochem Biophys Res Commun. 2016 Oct 21;479 (3) :424-428.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC040294-500 1x 500 µL
NKX2.2 (NX2/294), CF405S conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
